Tami Tillotson Martin - Aug 30, 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Sr. V.P., Regulatory Affairs
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Aug 30, 2023
Transactions value $
-$64,881
Form type
4
Date filed
9/1/2023, 05:00 PM
Previous filing
Aug 29, 2023
Next filing
Jan 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $194K +8.1K +9.5% $23.99 93.3K Aug 30, 2023 Direct
transaction SUPN Common Stock Sale -$259K -8.1K -8.68% $32.00 85.2K Aug 30, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -8.1K -36.82% $0.00 13.9K Aug 30, 2023 Common Stock 8.1K $23.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2 The option vests in four equal annual installments beginning on February 21, 2021.